LX102 gene therapy compared with aflibercept for wet age-related macular degeneration
Tests LX102, given once under the retina, against aflibercept in wet macular degeneration.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
Key facts
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi’an, Xingtai, Xuzhou, and Zhongshan, ChinaSee the 36 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 80 years old?
Source: NCT07317934, who can take part
Where in China
- Beijing Aier-Intech Eye HospitalBeijing, ChinaTaking people
- Beijing HospitalBeijing, ChinaTaking people
- Peking Union Medical College HospitalBeijing, ChinaTaking people
- The Second Hospital of Jilin UniversityChangchun, ChinaTaking people
- Aier Eye Hospital Group Co., LTD. Changsha Aier Eye HospitalChangsha, ChinaTaking people
- The Second Xiangya Hospital, Central South UniversityChangsha, ChinaTaking people
- Sichuan Provincial People's HospitalChengdu, ChinaTaking people
- West China Hospital，Sichuan UniversityChengdu, ChinaTaking people
- Southwest HospitalChongqing, ChinaTaking people
- The Second Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaTaking people
- The First Affiliated Hospital of Jinan UniversityGuangzhou, ChinaTaking people
- Zhejiang Provincial People's HospitalHangzhou, ChinaTaking people
- The Second Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaTaking people
- The First Affiliated Hospital of University of Science and Technology of ChinaHefei, ChinaTaking people
- Qilu Hospital of Shandong UniversityJinan, ChinaTaking people
- Shandong Eye HospitalJinan, ChinaTaking people
- The Affiliated Eye Hospital of Nanjing Medical UniversityNanjing, ChinaTaking people
- Qingdao Eye Hospital Affiliated to Shandong First Medical UniversityQingdao, ChinaTaking people
- Eye ENT Hospital of Fudan UniversityShanghai, ChinaTaking people
- Ruijin Hospital Affiliated to Shanghai Jiaotong University School of MedicineShanghai, ChinaTaking people
- Shanghai General HospitalShanghai, ChinaTaking people
- Xinhua Hospital Affiliated To Shanghai Jiao tong University School of MedicineShanghai, ChinaTaking people
- Joint Shantou International Eye Center, Shantou University and the Chinese University of Hong KongShantou, ChinaTaking people
- Shenyang Fourth People's HospitalShenyang, ChinaTaking people
- Shanxi Bethune HospitalTaiyuan, ChinaTaking people
- Shanxi Eye HospitalTaiyuan, ChinaTaking people
- Tianjin Eye HospitalTianjin, ChinaTaking people
- Tianjin Medical University Eye HospitalTianjin, ChinaTaking people
- The Eye Hospital of Wenzhou Medical UniversityWenzhou, ChinaTaking people
- Central Theater Command General Hospital of PLAWuhan, ChinaTaking people
- Tongji Hospital Tongji Medical College of HustWuhan, ChinaTaking people
- The First Affiliated Hospital of Air Force Medical UniversityXi’an, ChinaTaking people
- Xi 'an People's Hospital (Xi 'an No.4 Hospital)Xi’an, ChinaTaking people
- Hebei Eye HospitalXingtai, ChinaTaking people
- Xuzhou First People's HospitalXuzhou, ChinaTaking people
- Zhongshan Ophthalmic Center, Sun Yat-sen UniversityZhongshan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Innostellar Biotherapeutics Co.,Ltd
- Trial code
- NCT07317934
- Record updated
- 6 August 2026
- Original description
This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration. The study will evaluate a single subretinal injection of LX102 compared to an active comparator. The primary endpoint of this study is the mean change from D0 in BCVA based on an average at weeks 48 and 56.Read full original descriptionShow less
A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants With Neovascular Age-Related Macular Degeneration - The STELLAR Trial
This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration. The study will evaluate a single subretinal injection of LX102 compared to an active comparator. The primary endpoint of this study is the mean change from D0 in BCVA based on an average at weeks 48 and 56.
Inclusion: Willing and able to provide written, signed informed consent for this study; Age ≥50 and ≤80 years old; Active CNV secondary to nAMD in the study eye confirmed by FFA or OCT; The BCVA between 24 and 78 letters (inclusive) in the study eye at Screening; Demonstrated clinical response to aflibercept treatments in the study eye confirmed by the Reading Center; No anti-VEGF therapy in study eye within 28 days before screening; Must be pseudophakic in the study eye.
Exclusion: History of intraocular surgery within 1 month before screening in the study eye; Any condition in the investigator's opinion that could limit VA improvement in the study eye; History of retinal detachment in the study eye at any time; History of idiopathic or autoimmune uveitis in either eye; History of vitrectomy surgery in the study eye; History of ocular or systemic gene therapy; Recent myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months; CNV or macular edema in the study eye secondary to any causes other than AMD; Subfoveal atrophy in the study eye, as determined by CRC; Advanced glaucoma in the study eye.